Effect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment of Helicobacter pylori in Ningxia, China

Xiaoming Su; Yanhong Deng; Xianmei Chen; Yanling Li; Qian Hao; Yuanyuan Tang; Rui Mu; Yuting Wu; Yan Zhou; Shengjuan Hu

doi:10.3389/fmed.2024.1510376

Effect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment of Helicobacter pylori in Ningxia, China

Front Med (Lausanne). 2025 Jan 10:11:1510376. doi: 10.3389/fmed.2024.1510376. eCollection 2024.

Authors

Xiaoming Su¹, Yanhong Deng², Xianmei Chen², Yanling Li², Qian Hao², Yuanyuan Tang², Rui Mu², Yuting Wu², Yan Zhou³, Shengjuan Hu²

Affiliations

¹ Department of Gastroenterology, The Fifth People's Hospital of Ningxia Hui Autonomous Region, Shizuishan, Ningxia, China.
² Department of Gastroenterology, People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China.
³ Department of Infectious Diseases, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China.

Abstract

Introduction: Helicobacter pylori (H. pylori) is becoming more resistant to antibiotics, and the implementation of individualized therapy is highly valuable for its eradication. This study aimed to investigate the efficacy and safety of individualized treatment guided by antibiotic susceptibility testing (AST) with a 10-day or 14-day course for the eradication of H. pylori.

Methods: This was a prospective, open-label, single-center, quasi-randomized trial in which 220 participants were randomized into groups based on AST results as AST-10-day (n = 98) and AST-14-day (n = 112) treatment groups. All participants were retested for a 14-carbon urease breath test at weeks 4-8 after the end of the treatment.

Results: The primary resistance rates of H. pylori to metronidazole, levofloxacin, clarithromycin, and amoxicillin were 94.1% (207/220), 42.7% (95/220), 41.4% (91/220), and 0.9% (2/220), respectively; however, no resistance to furazolidone and tetracycline was observed. In the AST-10-day and AST-14-day groups, the intention-to-treat (ITT) eradication rates were 89.8% (88/98) and 90.2% (110/122), respectively, with no statistically significant difference (p = 0.928). The per-protocol (PP) eradication rates were 92.6% (88/95) and 98.2% (110/112), respectively, with a statistically significant difference (p = 0.049). The incidence rates of adverse events (AEs) in the AST-10-day and AST-14-day groups were 6.3% (6/95) and 7.2% (8/112), respectively, with no statistically significant difference (p = 0.813). No statistically significant difference was observed in compliance between the two groups (p = 0.467).

Conclusion: Both 10-day and 14-day AST guided individualized therapy can achieve satisfactory eradication effect. Compared with the 14-day regimen, the 10-day regimen has similar eradication rate and incidence of adverse events and compliance but shorter duration and lower cost.

Keywords: Helicobacter pylori; adverse events; antibiotic sensitivity test; eradication rate; individualized therapy.

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Key Research and Development Program of Ningxia Hui Autonomous Region (No. 2019BFG02003 and No. 2021BEG02025) and the Special Project for Benefiting the People with Science and Technology of Ningxia Hui Autonomous Region (No. 2022CMG03039).